🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Iovance's lead candidate shows positive effect in mid-stage melanoma study; shares ahead 7% premarket

Published 11/09/2017, 09:21 AM
© Reuters.  Iovance's lead candidate shows positive effect in mid-stage melanoma study; shares ahead 7% premarket
IOVA
-
  • Iovance Biotherapeutics (NASDAQ:IOVA) is up 7% premarket on light volume on the heels of positive data from a Phase 2 clinical trial assessing lead candidate LN-144 in metastatic melanoma patients. The results will be presented tomorrow, November 10, at the SITC Annual Meeting in National Harbor, MD.
  • The data showed administration with its Generation 2 manufacturing process resulted in a disease control rate of 78% (n=7/9), including three confirmed partial responders and one unconfirmed partial responder. The four had a median of four prior lines of therapy.
  • Fast Track- and Orphan Drug-tagged LN-144 is an autologous cancer therapeutic based on tumor infiltrating lymphocytes (TILs). TILs are isolated from a patient's resected tumor, expanded in vitro away from the cancer's immune-suppressing effects and then infused into the patient who has been preconditioned to remove all suppressive influences.
  • Now read: Prima Biomed: Encouraging Data At SITC


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.